

## IIB Dashboard (FY2017/18)

### Mission statement

The Infections and Immunity Board is responsible for MRC's investments in understanding infectious human disease and disorders of the human immune system. The Board seeks to extend our understanding of human pathogens, as well as the normal development and functioning of the human immune system. The Board makes a significant contribution to the MRC's Global Health Research portfolio both through its response mode and strategic investments, including the Africa Units.

#### Award rate by Research Board

(by number and % across a 3yr average)

Grant type	IIB	MCMB	NMHB	PSMB
Research	28/158 18%	34/184 18%	32/215 15%	22/177 13%
NIRGs	7/22 31%	4/23 19%	5/32 16%	6/22 29%
Programme	5/9 52%	6/20 28%	5/14 37%	6/12 49%
Partnership	0/3 0%	4/9 44%	4/12 33%	4/14 29%
<b>Overall Award Rate</b>	<b>21%</b>	<b>22%</b>	<b>17%</b>	<b>17%</b>


#### Partnership funding

- **AMR India-UK Newton Call** (£5m) ESRC led cross-council AMR initiative call funded four interdisciplinary research consortia to address the challenge of AMR in India.
- **AMR in a Global Context GCRF Call** (£12.7m, 3 yrs) In partnership with DHSC, supported 10 development awards and four large interdisciplinary consortia in a One Health approach to understanding drivers of AMR in LMICs.

#### IIB Opportunities

- Global Health Momentum areas
- Immunity and Infection through the life course
- Data integration and systems approaches

#### Annual spend (£m) across categories



#### Major strategic investments in FY2017/18:

- **MRC Centre in Global Health Infections Analysis** (previously Centre for Outbreak Analysis and Modelling) (£5.0m, 5 yrs). Provided exceptional support beyond 10 years and additional one-off support to extend work in Vaccines and AMR
- **MRC Centre for Molecular Bacteriology and Infection** (£2.6m, 5 years). Second five-year centre support period
- **MRC Tropical Epidemiology Group** (£4.1m, 5 yrs) Strategic Research Programme Epidemiological and statistical research on health problems of low and middle-income countries
- **AMR Target Discovery and Validation GCRF Call** (£3m, 3 yrs) In partnership with MRC translation team, supported three consortia to develop and validate new targets, antibiotics and alternative therapies for bacterial infections of primary importance to those living in LMICs.
- **Vaccines – Linking and accelerating UK R&D** (£3m, 1 yr) award to MRC/BBSRC Vaccines R&D networks, to link with complementary UK investments and industry, and to extend range of vaccines to include UK Health priorities.

#### Key investment areas / messages

- Current IIB focus areas:- Global health; Anti Microbial Resistance; Pandemic Preparedness; Immunity & infection through the life course; chronic infection, co-morbidity, immunomodulation: From data to insight-data integration and systems approaches .
- International AMR strategy developed and implemented in partnership activities
- UK dimension embedded into our MRC/BBSRC Vaccines R&D networks
- MRC coordination of the UK (MRC, DHSC, DfID) funders response on the establishment of a WHO Global Coordinating Mechanism (GCM) for R&D to prevent & respond to epidemic
- Inflammatory mediated immune disease (IMID) workshop to inform future call